Skin Barrier and Autoimmunity-Mechanisms and Novel Therapeutic Approaches for Autoimmune Blistering Diseases of the Skin

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2019 Jun 4

PMID 31156638

Citations 12

Authors

Natalie E Stevens

Allison J Cowin

Zlatko Kopecki

Affiliations

Soon will be listed here.

Abstract

One of the most important functions of the skin besides regulating internal body temperature includes formation of the barrier between the organism and the external environment, hence protecting against pathogen invasion, chemical and physical assaults and unregulated loss of water and solutes. Disruption of the protective barrier is observed clinically in blisters and erosions of the skin that form in autoimmune blistering diseases where the body produces autoantibodies against structural proteins of the epidermis or the epidermal-dermal junction. Although there is no cure for autoimmune skin blistering diseases, immune suppressive therapies currently available offer opportunities for disease management. In cases where no treatment is sought, these disorders can lead to life threatening complications and current research efforts have focused on developing therapies that target autoantibodies which contribute to disease symptoms. This review will outline the involvement of the skin barrier in main skin-specific autoimmune blistering diseases by describing the mechanisms underpinning skin autoimmunity and review current progress in development of novel therapeutic approaches targeting the underlying causes of autoimmune skin blistering diseases.

Citing Articles

Enhancing Transcutaneous Drug Delivery: Advanced Perspectives on Skin Models.

Ribeiro A, Pereira-Leite C, Rosado C, Aruci E, Colley H, Kortekaas Krohn I JID Innov. 2025; 5(2):100340.

PMID: 39925780 PMC: 11803873. DOI: 10.1016/j.xjidi.2024.100340.

From traditional medicine to nanomedicine: potential of extracts in treating inflammatory skin diseases.

Phul I, Gomez-Llonin A, Bhaw-Luximon A RSC Med Chem. 2024; 15(8):2643-2656.

PMID: 39149101 PMC: 11324057. DOI: 10.1039/d4md00194j.

Adipose-derived stem cells in immune-related skin disease: a review of current research and underlying mechanisms.

Sun T, Zhou C, Lu F, Dong Z, Gao J, Li B Stem Cell Res Ther. 2024; 15(1):37.

PMID: 38331803 PMC: 10854049. DOI: 10.1186/s13287-023-03561-8.

The immunomodulatory activity of against atopic dermatitis: Evidence-based on network pharmacology and molecular simulations.

Pandaleke T, Handono K, Widasmara D, Susianti H J Taibah Univ Med Sci. 2023; 19(1):164-174.

PMID: 38047238 PMC: 10692725. DOI: 10.1016/j.jtumed.2023.10.005.

The gut microbiome in bullous pemphigoid: implications of the gut-skin axis for disease susceptibility.

Liu X, van Beek N, Cepic A, Andreani N, Chung C, Hermes B Front Immunol. 2023; 14:1212551.

PMID: 38022583 PMC: 10668026. DOI: 10.3389/fimmu.2023.1212551.

References

Ding X, Diaz L, Fairley J, Giudice G, Liu Z . The anti-desmoglein 1 autoantibodies in pemphigus vulgaris sera are pathogenic. J Invest Dermatol. 1999; 112(5):739-43. DOI: 10.1046/j.1523-1747.1999.00585.x. View

Amagai M . Autoimmunity against desmosomal cadherins in pemphigus. J Dermatol Sci. 1999; 20(2):92-102. DOI: 10.1016/s0923-1811(99)00016-x. View

Toto P, Feliciani C, Amerio P, Suzuki H, Wang B, Shivji G . Immune modulation in pemphigus vulgaris: role of CD28 and IL-10. J Immunol. 1999; 164(1):522-9. DOI: 10.4049/jimmunol.164.1.522. View

Jonkman M, Schuur J, Dijk F, Heeres K, de Jong M, van der Meer J . Inflammatory variant of epidermolysis bullosa acquisita with IgG autoantibodies against type VII collagen and laminin alpha3. Arch Dermatol. 2000; 136(2):227-31. DOI: 10.1001/archderm.136.2.227. View

Proby C, Ota T, Suzuki H, Koyasu S, Gamou S, Shimizu N . Development of chimeric molecules for recognition and targeting of antigen-specific B cells in pemphigus vulgaris. Br J Dermatol. 2000; 142(2):321-30. DOI: 10.1046/j.1365-2133.2000.03328.x. View

Chan L . Epitope spreading in paraneoplastic pemphigus: autoimmune induction in antibody-mediated blistering skin diseases. Arch Dermatol. 2000; 136(5):663-4. DOI: 10.1001/archderm.136.5.663. View

Nguyen V, Ndoye A, Grando S . Novel human alpha9 acetylcholine receptor regulating keratinocyte adhesion is targeted by Pemphigus vulgaris autoimmunity. Am J Pathol. 2000; 157(4):1377-91. PMC: 1850172. DOI: 10.1016/s0002-9440(10)64651-2. View

Powell A, Black M . Epitope spreading: protection from pathogens, but propagation of autoimmunity?. Clin Exp Dermatol. 2001; 26(5):427-33. DOI: 10.1046/j.1365-2230.2001.00852.x. View

Sitaru C, Kromminga A, Hashimoto T, Brocker E, Zillikens D . Autoantibodies to type VII collagen mediate Fcgamma-dependent neutrophil activation and induce dermal-epidermal separation in cryosections of human skin. Am J Pathol. 2002; 161(1):301-11. PMC: 1850704. DOI: 10.1016/s0002-9440(10)64182-x. View

10.

Sawamura D, McMillan J, Akiyama M, Shimizu H . Epidermolysis bullosa: directions for future research and new challenges for treatment. Arch Dermatol Res. 2003; 295 Suppl 1:S34-42. DOI: 10.1007/s00403-002-0370-7. View

11.

Koivukangas V, Oikarinen A . Suction blister model of wound healing. Methods Mol Med. 2003; 78:255-61. DOI: 10.1385/1-59259-332-1:255. View

12.

Aoki V, Millikan R, Rivitti E, Hans-Filho G, Eaton D, Warren S . Environmental risk factors in endemic pemphigus foliaceus (fogo selvagem). J Investig Dermatol Symp Proc. 2004; 9(1):34-40. DOI: 10.1111/j.1087-0024.2004.00833.x. View

13.

Sanchez-Palacios C, Chan L . Development of pemphigus herpetiformis in a patient with psoriasis receiving UV-light treatment. J Cutan Pathol. 2004; 31(4):346-9. DOI: 10.1111/j.0303-6987.2004.0188.x. View

14.

Veldman C, Hohne A, Dieckmann D, Schuler G, Hertl M . Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. J Immunol. 2004; 172(10):6468-75. DOI: 10.4049/jimmunol.172.10.6468. View

15.

Hoyer B, Moser K, Hauser A, Peddinghaus A, Voigt C, Eilat D . Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med. 2004; 199(11):1577-84. PMC: 2211779. DOI: 10.1084/jem.20040168. View

16.

Berookhim B, Fischer H, Weinberg J . Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept. Cutis. 2004; 74(4):245-7. View

17.

Yancey K . The pathophysiology of autoimmune blistering diseases. J Clin Invest. 2005; 115(4):825-8. PMC: 1070439. DOI: 10.1172/JCI24855. View

18.

Waschke J, Bruggeman P, Baumgartner W, Zillikens D, Drenckhahn D . Pemphigus foliaceus IgG causes dissociation of desmoglein 1-containing junctions without blocking desmoglein 1 transinteraction. J Clin Invest. 2005; 115(11):3157-65. PMC: 1242188. DOI: 10.1172/JCI23475. View

19.

Melani L, Giomi B, Antiga E, Torchia D, Caproni M, Fabbri P . Radiation therapy as a trigger factor for initially localized bullous pemphigoid. Breast J. 2005; 11(6):485-6. DOI: 10.1111/j.1075-122X.2005.00150.x. View

20.

Fujinami R, von Herrath M, Christen U, Whitton J . Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev. 2006; 19(1):80-94. PMC: 1360274. DOI: 10.1128/CMR.19.1.80-94.2006. View